Trump Executive Order: Accelerating Psychedelic Therapies
- —The April 18 executive order does not grant immediate FDA approval but ends the era of federal prohibition for research, signaling a science-driven shift toward neuroplastic therapy
- —Key fast-track mechanisms include National Priority Vouchers (significantly reduced review time), weeks-long Schedule I rescheduling after successful Phase 3, and a Right to Try pathway for treatment-resistant patients #催化劑
- —The order compels the VA to collaborate more aggressively with the private sector and designates five VA facilities as Innovative Therapies Centers of Excellence #催化劑
- —$50M federal allocation to Texas' stalled ibogaine program allows independent clinical trials at state universities without private pharmaceutical partners #催化劑
$CMPS 有望獲得 National Priority Voucher
- —The order's voucher pathway may reopen the route for Compass Pathways to receive a breakthrough therapy voucher after it was pulled in January; a recent weight-loss drug with a voucher was approved in under a month #催化劑
KOL 精神科藥物持股：投資時機在商業化前夕
- —KOL holds two psychedelic stocks (up 80% and 15% respectively) and describes the executive order as 'a big shot in the arm' to his existing positions
- —Investment thesis is timing-based: enter just before commercialization; the executive order accelerates that timeline significantly
Ibogaine：政治熱情 vs 醫學風險
- —Ibogaine is a Schedule I substance linked to over 30 deaths from cardiovascular toxicity — a large number relative to the small number of trials conducted, making it generally low-priority in the research community #風險
- —Political momentum driven by Rick Perry, RFK Jr., and FDA Commissioner Makary; however, pharmaceutical companies have so far declined to participate in ibogaine programs #風險
- —The order broadened from ibogaine-exclusive to the wider category of neuroplastic therapy due to significant pushback